Shares of Cochlear Limited (ASX: COH) are inching forward on Thursday to trade 56 basis points higher at $225.98.
After a swift recovery in March, where shares thrust off a bottom of $190 – from $182 in January as well – Cochlear is now trading 4% higher this year.
Is Cochlear a buy?
Analysts have turned more constructive on the company since it released its first half results earlier this year.
Since then, the number of brokers advocating to buy Cochlear has surged to 42%, in line with the percentage of holds.
Still, almost 16% of coverage reckons to sell the stock right now, with RBC Capital Markets pricing a $149 per share valuation on Cochlear.
However, despite the balanced view, Cochlear is trading above its consensus price target of $221.18 apiece.
Analysts at JP Morgan were clearly impressed by the company’s latest earnings, noting the “strong result signals [its] growth story [is] clearly intact,” in a recent note.
“Cochlear reported a strong first half as European and emerging market implant volumes recovered, despite headwinds from multiple COVID waves,” it said.
“The result was also supported by a sharp lift in Services revenue as upgrades lifted as well as very strong Acoustic sales growth. This result signals the recovery is now broad-based, with the pandemic headwinds now manageable confirming the resilience of the growth story,” the broker added.
Given its performance, JP Morgan has now dampened its concerns surrounding the maker and researcher of cochlear implant systems.
However, valuation remains a concern, and with some foreseeable challenges ahead, the broker is comfortable on the sidelines at a neutral rating.
“Cochlear’s key markets have recovered more rapidly than we had feared given this results strong beat…we think the company is well positioned to return to its strong historical growth profile,” it noted.
“While the medium-term outlook remains compelling with the stock trading at its 5 year average [price to earnings] P/E and with limited upside to our DCF-based price target, we have retained our neutral rating (June 2022 price target lifted to $223 from $207).”
The post The Cochlear share price has shaved 13% from its all-time high. Is now the time to pounce? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Cochlear right now?
Before you consider Cochlear, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- ASX 200 healthcare shares were chronically ill last quarter. Take a look
- What’s the outlook for the Cochlear share price in April?
- 3 more of the ‘best’ ASX 200 shares to buy this month: Morgans
- Why is the Cochlear (ASX:COH) share price sliding today?
- 3 ASX healthcare shares rated as buys by a leading broker
Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/t0z1ch9
Leave a Reply